Biotech China 2014

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Predictive markers for response to EGFR-targeted treatment in colorectal cancer Journal of Clinical Oncology. Epub 2010 Jan 25.
2. 2010 Isogenic mutant human cells as a new tool for personalized cancer medicine Cell Cycle. Jan 1;9(1):20-1. Epub 2010 Jan 29.
3. 2010 Tracking the genomic evolution of breast cancer metastasis Breast Cancer Research. 12:302 (2 February 2010)
4. 2010 The prognostic IDH1 ( R132 ) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma Acta Neuropathol. Feb 4. [Epub ahead of print]
5. 2009 Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute. Oct 7;101(19):1308-24. Epub 2009 Sep 8. Review.
6. 2009 Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS One. Oct 2;4(10):e7287.
7. 2009 Selective cytotoxicity in cancer cells expressing K-Ras(G13D) of a bicyclic Ras inhibitor Biochem Biophys Res Commun. Sep 4;386(4):593-7. Epub 2009 Jun 18
8. 2009 Molecular Profiling of the Plexinome in melanoma and pancreatic cancer Human Mutation. Aug;30(8):1167-74.
9. 2009 Mutational profile of GNAQQ209 in human tumors. PLoS One. Aug 31;4(8):e6833.
10. 2009 Expression and Functional Regulation of Myoglobin in Epithelial Cancers American Journal of Pathology . Jul;175(1):201-6.
11. 2009 Absence of AKT1 mutations in glioblastoma PLoS One. May 20;4(5):e5638.
12. 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Research. Mar 1;69(5):1851-7. Epub 2009 Feb 17.
13. 2009 Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes Human Mutation. Feb;30(2):E451-9
14. 2009 IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors Human Mutation. Jan;30(1):7-11
15. 2009 Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer. Oct 20;101(8):1261-8. Epub 2009 Sep 22
16. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer Journal of Clinical Oncology. Dec 10;26(35):5705-12. Epub 2008 Nov 10.
17. 2008 Understanding how kinase-targeted therapies work Cell Cycle. Jun 1;7(11):1560-3. Epub 2008 Mar 30.
18. 2008 AKT1 (E17K) in human solid tumours Oncogene. May 26 [Epub ahead of print]
19. 2008 PIK3CA cancer mutations display gender and tissue specificity patterns Human Mutation. Feb;29(2):284-8
20. 2008 PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer Breast Cancer Research. 10(2):R27. Epub 2008 Mar 27..
21. 2008 Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dec 30;105(52):20864-9. Epub 2008 Dec 23
22. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Research. Mar 15;67(6):2643-8
23. 2007 Genomic landscapes of cancers: prospects for targeted therapies Pharmacogenomics. Dec;8(12):1629-33
24. 2007 Knock-in of oncogenic KRAS does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers Cancer Research. Sep 15;67(18):8468-76
25. 2007 Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells Cancer Research. Aug 1;67(15):7088-94
26. 2007 Genetic targeting the kinase activity of the Met receptor in cancer cells Proceedings of the National Academy of Sciences of the United States of America. Jul 3;104(27):11412-17
27. 2007 Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma Cancer Research. Apr 15;67(8):3545-50
28. 2006 Kinase mutations in cancer: chinks in the enemy s armour ? Current Opinion in Oncology. Jan;18(1):69-76. Review
29. 2005 PRL-3 phosphatase is implicated in ovarian cancer growth Clinical Cancer Research. Oct 1;11(19 Pt 1):6835-9
30. 2005 Genetic analysis of the kinome and phosphatome in cancer Cellular and Molecular Life Sciences. Sep; 62(18):2092-9
31. 2005 Colorectal cancer: Mutations in a signalling pathway Nature. Aug 11;436(7052):792
32. 2005 Somatic mutation of EGFR catalytic domain and treatment with Gefitinib in colorectal cancer Annals of Oncology. Nov;16(11):1848-9
33. 2005 Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer Cancer Research. Dec 1; 65(23):11227
34. 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study LANCET Oncology. May; 6(5):279-86
35. 2005 Identification of cancer genes by mutational profiling of tumor genomes FEBS Letters. Mar 21;579(8):1884-90. Review
36. 2005 Mutational analysis of gene families in human cancer Current Opinion in Genetics and Development. Feb;15(1):5-12
37. 2005 Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells Molecular Cancer Therapeutics. Jun;4(6):1026-30
38. 2004 PRL-3: A Phosphatase for Metastasis? Cancer Biology & Therapy. Oct;3(10):952-3 [Epub 2004 Oct 8]
39. 2004 Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Research. Dec 15;64(24):8816-20
40. 2004 SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells Proceedings of the National Academy of Sciences of the United States of America. Nov 30;101(48):16897-902 [Epub 2004 Nov 19]
41. 2004 Alterations in vascular gene expression in invasive breast carcinoma Cancer Research. Nov 1;64(21):7857-66 [Erratum in: Cancer Res. 2004 Dec 1;64(23): 8794]
42. 2004 Mutational analysis of the tyrosine phosphatome in colorectal cancers Science. May 21;304(5674):1164-6
43. 2004 High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science. Apr 23;304(5670):554 [Epub 2004 Mar 11]
44. 2004 Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-FU in metastatic colorectal cancer patients Proceedings of the National Academy of Sciences of the United States of America. Mar 2;101(9):3089-94 [Epub 2004 Feb 17]
45. 2004 p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells Cancer Biology & Therapy. Feb;3(2):221-5 [Epub 2004 Feb 1]
46. 2003 Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers Science. May 9;300(5621):949
47. 2003 PRL-3 Expression in metastatic cancers Clinical Cancer Research. Feb;3(2):221-5 [Epub 2004 Feb 1]
48. 2003 Identifying Tumor Origin Using a Gene Expression Based Classification Map Cancer Research. Jul 15;63(14):4144-9.
49. 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature. Aug 29;418(6901):934
50. 2001 Carcinogen-Specific Induction of Genetic Instability Proceedings of the National Academy of Sciences of the United States of America. May 8;98(10):5770-5 [Epub 2001 Apr 10]
51. 2001 Receptor tyrosine kinases as therapeutic targets Current Drug Targets. Mar;2(1):41-55. Review
52. 2001 A Phosphatase Associated With Metastasis of Colorectal Cancer Science. Nov 9;294(5545):1343-6 [Epub 2001 Oct 11]
53. 2000 Different Point Mutations In The MET Oncogene Elicit Distinct Biological Properties Faseb Journal. 14(2): 399-406
54. 1999 A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth Journal Of Biological Chemistry. Oct 8;274(41):29274-81
55. 1999 Mutant Met-Mediated Transformation Is Ligand-Dependent And Can Be Inhibited By HGF Antagonists Oncogene. Sept 16;18(37):5221-31
56. 1999 Loss of The Exon Encoding The Juxtamembrane Domain Is Essential For The Oncogenic Activation of TPR-MET Oncogene. Jul 22;18(29):4275-81
57. 1999 Novel Mutation In The ATP Binding Site of The MET Oncogene Tyrosine Kinase In A HPRCC Family International Journal Of Cancer. Aug 27;82 (5):640-3
58. 1999 MET(PRC) Mutations In The RON Receptor Result In Upregulation of Tyrosine Kinase Activity And Acquisition of Oncogenic Potential Journal of Cellular Physiology. Dec;181(3):507-14
59. 1999 Concomitant Activation of Pathways Downstream of Grb2 and PI 3-Kinase Is Required For Met-Mediated Metastasis Oncogene. Feb 4;18(5):1139-46
60. 1998 Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met Biochemical Journal. Nov 15;336 ( Pt 1):235-9
61. 1998 Induction of epithelial tubules by growth factor HGF depends on the STAT pathway Nature. Jan 15;391(6664):285-8
62. 1998 Uncoupling Signal Transducers from Oncogenic MET Mutants Abrogates Cell Transformation and Inhibits Invasive Growth Proceedings of the National Academy of Sciences of the United States of America. Nov 24;95(24):14379-83
63. 1997 A Point Mutation In The Met Oncogene Abrogates Metastasis Without Affecting Transformation Proceedings of the National Academy of Sciences of the United States of America. Dec 9;94(25):13868-72
64. 1997 GAB1 Coupling To The HGF/MET Receptor Multifunctional Docking Site Requires Binding of Grb2 and Correlates with the Transforming Potential Oncogene. Dec 18;15(25):3103-11
65. 1997 Invasive-Growth Signaling by The Met/HGF Receptor: the Hereditary Renal Carcinoma Connection Biochimica et Biophysica Acta-Reviews on Cancer. Dec 9;1333(3):M41-51. Review
66. 1997 Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2 Oncogene. Feb 13;14(6):705-11
67. 1997 Scatter factor receptors are key players in a unique multistep program leading to invasive growth Ciba Found Symp. 212:133-44; discussion 144-7. Review
68. 1996 The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma Molecular And Cellular Biology. 1996 May;16(5):2151-63
69. 1996 Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility Journal Of Biological Chemistry. Jun 14;271(24):14119-23
70. 1995 Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction Journal Of Biological Chemistry. Jan 13;270(2):603-11
71. 1995 The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein Oncogene. Apr 20;10(8):1631-8
72. 1994 Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering Journal of Biotechnology. Sep 30;37(2):109-22. Review
73. 1994 Hepatocyte Growth Factor And Its Receptor, The Tyrosine Kinase Encoded By The C-Met Proto-Oncogene Cellular And Molecular Biology. Jul;40(5):597-604. Review
74. 1994 A Multifunctional Docking Site Mediates Signalling And Transformation By The Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor Family Cell. Apr 22;77(2):261-71
75. 1994 Tyrosine1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor) Oncogene. Jan;9(1):49-57
76. 1993 A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor Molecular And Cellular Biology. Aug;13(8):4600-8
77. 1992 Autophosphorylation Promotes Complex Formation of Recombinant Hepatocyte Growth Factor Receptor With Cytoplasmic Effectors Containing SH2 Domains Oncogene. Oct;7(10):1973-8
78. 1991 Scatter Factor And Hepatocyte Growth Factor Are Indistinguishable Ligands For The Met Receptor EMBO Journal. Oct;10(10):2867-78

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.